Clinical trial
Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects
NCT00293033 · BioDelivery Sciences International, Industry · Completed
Key facts
| NCT number | NCT00293033 |
|---|---|
| Title | Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects |
| Official title | A Double-blind, Placebo Controlled Evaluation of the Efficacy, Safety and Tolerability of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects |
| Lead sponsor | BioDelivery Sciences International, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pain, Cancer |
| Intervention type | Drug |
| Interventions | BEMA™, Placebo |
| Enrollment | 152 |
| Start date | Feb 1, 2006 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Feb 17, 2006 |
| Last update posted | Nov 18, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: